1. Others
  2. Others
  3. BNTA

BNTA 

Cat. No.: HY-136651
Handling Instructions

BNTA is a small molecule with extracellular matrix (ECM) modulatory properties, and it facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA is a potential therapeutic agent in osteoarthritis.

For research use only. We do not sell to patients.

BNTA Chemical Structure

BNTA Chemical Structure

CAS No. : 685119-25-9

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BNTA is a small molecule with extracellular matrix (ECM) modulatory properties, and it facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA is a potential therapeutic agent in osteoarthritis[1].

In Vitro

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes[1].
BNTA (0.1 μM; 2 d) increases SOX9 protein markedly[1].
BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes[1].
BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells[1].
BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes[1].
BNTA (0.01-10 μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes[1].
BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants[1].

Cell Viability Assay[1]

Cell Line: Human OA chondrocytes
Concentration: 0.01, 0.1, 1, 10 μM
Incubation Time: 1, 3, 5, 7 d
Result: No toxicity was observed.

Western Blot Analysis[1]

Cell Line: Human OA chondrocytes
Concentration: 0.1 μM
Incubation Time: 2 d
Result: Elevated SOX9 protein compared with vehicle.
In Vivo

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats[1].

Animal Model: Male SD rats weighing 80 g are induced by ACLT[1]
Dosage: 0.015, 0.15, 1.5 mg/kg
Administration: Intra-articular injection; twice a week for 4 and 8 weeks
Result: Attenuated post-traumatic osteoarthritis development after intra-articular injection for 4 and 8 weeks and was well tolerated.
Molecular Weight

456.76

Formula

C₁₇H₁₁BrClNO₃S₂

CAS No.

685119-25-9

SMILES

O=C(NC1=C(Br)SC=C1S(=O)(C2=CC=CC=C2)=O)C3=CC=CC=C3Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

BNTAOthersextracellularmatrixECMmodulatorypropertiescartilagechondrocytessuperoxidedismutase3SOD3osteoarthritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BNTA
Cat. No.:
HY-136651
Quantity:
MCE Japan Authorized Agent: